AHA Coding Clinic® for ICD-10-CM and ICD-10-PCS - 2020 Issue 4; Section X-New Technology
Transfusion of Chimeric Antigen Receptor (CAR) T Cell Immunotherapy
New table XW2, Anatomical Regions, Transfusion, provides two new codes to describe the intravenous administration of two immunotherapy products as noted below. Body Part Device/Substance/Technology 3 Peripheral Vein 4 Central Vein 4 Brexucabtagene Autoleucel Immunotherapy 7 Lisocabtagene Maraleucel Immunotherapy Unlike other current chimeric antigen receptor (CAR) T-cell therapy products which are classified in table XW0, Anatomical Regions, Introduction, Brexucabtagene Autoleucel Immunotherapy and Lisocabtagene Maraleucel Immunotherapy are classified under the root operation Transfusion based on the root operation definitions and receipt of public comments. CAR T-cell therapy is comprised of blood/blood products; therefore, the root operation Transfusion is more clinically...
Subscribe or sign in to view the full article.
Article Overview
This article explains an ICD-10-PCS coding update related to CAR T-cell immunotherapy administration. It focuses on how select immunotherapy products are classified within the PCS framework, why the classification approach changed, and the broader context of the 2020 ICD-10 Coordination and Maintenance Committee discussion. The article is relevant to coding professionals working with inpatient procedure coding, hematology/oncology services, and biologic or cellular therapy administration.
Why This Topic Matters
Accurate procedure classification for CAR T-cell immunotherapy affects code selection, reporting consistency, and documentation interpretation for complex cellular therapies. The article helps coders and compliance teams understand the scope of the ICD-10-PCS update and the types of therapies affected.
Article Sections
-
New table XW2 and classification overview
Introduces the new ICD-10-PCS table structure associated with transfusion reporting and explains the general scope of the classification update.
-
Brexucabtagene Autoleucel Immunotherapy
Describes one of the immunotherapy products discussed in the article, including its general therapeutic context and administration format.
-
Lisocabtagene Maraleucel Immunotherapy
Describes the second immunotherapy product discussed in the article, including its general therapeutic context and administration format.
What You Will Learn
- How selected CAR T-cell immunotherapy procedures are addressed in ICD-10-PCS
- What broader classification changes are being discussed for cellular therapy administration
- Which immunotherapy products are the focus of the article
- How the article frames the relationship between procedure classification and committee review
Who Should Read This
- Inpatient coders
- Clinical documentation specialists
- Coding educators
- Revenue cycle professionals
- Compliance teams
- Hematology/oncology coding staff
Codes Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com